Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

Dec 20, 2021 | Press Releases

CUPERTINO, Calif., Dec. 20, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Nov 15, 2021 | Press Releases

– Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end – – Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with...

Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference

Sep 15, 2021 | Press Releases

CUPERTINO, Calif., Sept. 15, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 2, 2021 | Press Releases

CUPERTINO, Calif., Sept. 02, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Aug 16, 2021 | Press Releases

-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4’21 -$35.8 Million in Cash as of June 30, 2021 CUPERTINO, Calif., Aug. 16,...